PDA

View Full Version : US Oncology Research Network Participates In Phase III Follow-up Study To BiPar's Inv


News
07-21-2009, 04:15 AM
US Oncology, Inc. today announced that US Oncology Research will participate in the BiPar Sciences' Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or without BSI-201, in patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2-negative metastatic breast cancer. Joyce O'Shaughnessy, M.D.

More... (http://www.medicalnewstoday.com/articles/158135.php)